92Bio, Inc.
Company Profile
92Bio, Inc. is a biotechnology entity focused on the creation of novel, best-in-class multispecific biologics aimed at cancer treatment. Utilizing state-of-the-art technology and profound oncology knowledge, 92Bio strives to enhance antibody research and development. The company is based in Hayward, California, fostering a dynamic and inclusive work environment that values creativity, curiosity, independence, and perseverance.
Strategic Alliances
A significant partnership has been formed with Leveragen, effective May 30, 2024. This alliance focuses on the advancement of multi-specific antibodies, taking advantage of Leveragen's industry-leading technology and the innovation within single domain antibody platforms.
Leadership Team
- Dr. Ben Buelow, MD, PhD - Chief Executive Officer and Co-Founder. He previously served as CEO of Ancora Biotech and was the Chief Medical Officer at Teneobio, Inc., which was acquired by Amgen. Dr. Buelow holds an MD with honors and a PhD in Immunology from the University of Washington.
- Dr. Suhasini (Suhas) Iyer, PhD - Chief Development Officer, brings over 25 years of biotechnology sector experience, steering the strategic direction and development operations of 92Bio from the U.S.
- Patrick Koenig, PhD - Vice President, Biologics, is instrumental in driving 92Bio's mission to revolutionize cancer treatment through biologics.
Board of Directors
- Jeff Bird, MD, PhD - Board member and Managing Director at Bluebird Ventures, with a notable investment history in biotechnology.
- Olivia Bloom - Former Executive Vice President and CFO of Geron Corporation, with extensive experience in financial management and strategic governance.
Financial Activities
Currently, 92Bio has not engaged in funding rounds and is devoid of institutional or angel investors. Despite this, strategic alliances and the expertise of the leadership team continue to advance their research initiatives and market strategies.
Recent News and Publications
The collaboration with Leveragen marks a strategic initiative aligning with the company's goal to revolutionize cancer treatment through advanced antibody therapeutics. More updates and details are provided continuously through their [news and publications platform](https://92biotech.com/news-publication/).
Competitor Profile
Overview of Competitors
92Bio faces competition from industry leaders such as Amgen, Biogen, and Bristol Myers Squibb, which possess a substantial presence in the biotechnology and pharmaceutical sectors.
Amgen
Founded in 1980, Amgen stands as a biotechnology innovator, advancing patient health through therapies that target key therapeutic areas, including oncology and inflammatory diseases. Amgen's extensive research and development capabilities drive their robust therapeutic pipeline. Recognized within the Dow Jones Industrial Average, Amgen is also committed to ethical standards and social responsibility, integrating cutting-edge technologies like AI into their operations.
Biogen
Biogen was established in 1978 and focuses on neurological and neurodegenerative diseases, operating in over 80 countries. Known for their transformative healthcare contributions, Biogen emphasizes diverse clinical trials and health equity. Their leadership in neurology and immunology is a testament to their innovative science and patient-centered mission.
Bristol Myers Squibb
BMS is a global biopharmaceutical leader committed to delivering innovative medicines for serious diseases. Operating with agility and a focus on oncology, cardiovascular, and immune disorders, BMS combines scientific expertise with strategic business efforts to advance global health equity.
Other Notable Competitors
- BeiGene prioritizes affordable oncology treatment accessibility, expanding operations to over 45 countries alongside numerous clinical trials.
- Moderna employs its renowned mRNA technology platform for significant contributions in vaccine development, with its COVID-19 vaccine attaining global recognition.
These organizations craft a competitive ecosystem for 92Bio, underscoring the importance of differentiating its capabilities and strategic outlook within the biotechnology sphere.
